Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 101

1.

Disproportionate presentation of high risk prostate cancer in a safety net health system.

Porten SP, Richardson DA, Odisho AY, McAninch JW, Carroll PR, Cooperberg MR.

J Urol. 2010 Nov;184(5):1931-6. doi: 10.1016/j.juro.2010.06.116. Epub 2010 Sep 17.

PMID:
20846693
[PubMed - indexed for MEDLINE]
2.

Ability of 2 pretreatment risk assessment methods to predict prostate cancer recurrence after radical prostatectomy: data from CaPSURE.

Mitchell JA, Cooperberg MR, Elkin EP, Lubeck DP, Mehta SS, Kane CJ, Carroll PR.

J Urol. 2005 Apr;173(4):1126-31.

PMID:
15758720
[PubMed - indexed for MEDLINE]
3.

Sociodemographic and clinical risk characteristics of patients with prostate cancer within the Veterans Affairs health care system: data from CaPSURE.

Cooperberg M, Lubeck DP, Penson D, Mehta SS, Carroll PR, Kane CJ.

J Urol. 2003 Sep;170(3):905-8.

PMID:
12913727
[PubMed - indexed for MEDLINE]
4.

Prostate brachytherapy: a descriptive analysis from CaPSURE.

Lee WR, Sharkey J, Cowan JE, DuChane J, Carroll PR; CaPSURE Investigators.

Brachytherapy. 2007 Apr-Jun;6(2):123-8.

PMID:
17434105
[PubMed - indexed for MEDLINE]
5.

Predicting recurrence after radical prostatectomy for patients with high risk prostate cancer.

Grossfeld GD, Latini DM, Lubeck DP, Mehta SS, Carroll PR.

J Urol. 2003 Jan;169(1):157-63.

PMID:
12478126
[PubMed - indexed for MEDLINE]
6.

Sociodemographic predictors of prostate cancer risk category at diagnosis: unique patterns of significant and insignificant disease.

Dall'era MA, Hosang N, Konety B, Cowan JE, Carroll PR.

J Urol. 2009 Apr;181(4):1622-7; discussion 1627. doi: 10.1016/j.juro.2008.11.123. Epub 2009 Feb 23.

PMID:
19230923
[PubMed - indexed for MEDLINE]
7.

Treatment of patients with high risk localized prostate cancer: results from cancer of the prostate strategic urological research endeavor (CaPSURE).

Meng MV, Elkin EP, Latini DM, Duchane J, Carroll PR.

J Urol. 2005 May;173(5):1557-61.

PMID:
15821485
[PubMed - indexed for MEDLINE]
8.

Is ethnicity an independent predictor of prostate cancer recurrence after radical prostatectomy?

Grossfeld GD, Latini DM, Downs T, Lubeck DP, Mehta SS, Carroll PR.

J Urol. 2002 Dec;168(6):2510-5.

PMID:
12441951
[PubMed - indexed for MEDLINE]
9.

The independent impact of extended pattern biopsy on prostate cancer stage migration.

Master VA, Chi T, Simko JP, Weinberg V, Carroll PR.

J Urol. 2005 Nov;174(5):1789-93; discussion 1793.

PMID:
16217288
[PubMed - indexed for MEDLINE]
10.

Obesity and prostate cancer clinical risk factors at presentation: data from CaPSURE.

Kane CJ, Bassett WW, Sadetsky N, Silva S, Wallace K, Pasta DJ, Cooperberg MR, Chan JM, Carroll PR.

J Urol. 2005 Mar;173(3):732-6.

PMID:
15711258
[PubMed - indexed for MEDLINE]
11.

Time trends and characteristics of men choosing watchful waiting for initial treatment of localized prostate cancer: results from CaPSURE.

Harlan SR, Cooperberg MR, Elkin E, Lubeck DP, Meng M, Mehta SS, Carroll PR.

J Urol. 2003 Nov;170(5):1804-7.

PMID:
14532780
[PubMed - indexed for MEDLINE]
12.

Predicting risk of prostate specific antigen recurrence after radical prostatectomy with the Center for Prostate Disease Research and Cancer of the Prostate Strategic Urologic Research Endeavor databases.

Moul JW, Connelly RR, Lubeck DP, Bauer JJ, Sun L, Flanders SC, Grossfeld GD, Carroll PR.

J Urol. 2001 Oct;166(4):1322-7.

PMID:
11547066
[PubMed - indexed for MEDLINE]
13.

Validity of the CAPRA score to predict biochemical recurrence-free survival after radical prostatectomy. Results from a european multicenter survey of 1,296 patients.

May M, Knoll N, Siegsmund M, Fahlenkamp D, Vogler H, Hoschke B, Gralla O.

J Urol. 2007 Nov;178(5):1957-62; discussion 1962. Epub 2007 Sep 17.

PMID:
17868719
[PubMed - indexed for MEDLINE]
14.

Reduced incidence of bony metastasis at initial prostate cancer diagnosis: data from CaPSURE.

Ryan CJ, Elkin EP, Small EJ, Duchane J, Carroll P.

Urol Oncol. 2006 Sep-Oct;24(5):396-402.

PMID:
16962488
[PubMed - indexed for MEDLINE]
15.

Prostate cancer treatment and ten-year survival among group/staff HMO and fee-for-service Medicare patients.

Potosky AL, Merrill RM, Riley GF, Taplin SH, Barlow W, Fireman BH, Lubitz JD.

Health Serv Res. 1999 Jun;34(2):525-46.

PMID:
10357289
[PubMed - indexed for MEDLINE]
Free PMC Article
16.

Agent Orange exposure, Vietnam War veterans, and the risk of prostate cancer.

Chamie K, DeVere White RW, Lee D, Ok JH, Ellison LM.

Cancer. 2008 Nov 1;113(9):2464-70. doi: 10.1002/cncr.23695.

PMID:
18666213
[PubMed - indexed for MEDLINE]
Free Article
17.

High Gleason scores and lower prostate-specific antigen levels in a single institution over the past decade.

Abouelfadel Z, Miller GJ, Glode LM, Akduman B, Donohue RE, Nedrow A, Crawford ED.

Clin Prostate Cancer. 2002 Sep;1(2):115-7.

PMID:
15046702
[PubMed - indexed for MEDLINE]
18.

Bias due to missing SEER data in D'Amico risk stratification of prostate cancer.

Elliott SP, Johnson DP, Jarosek SL, Konety BR, Adejoro OO, Virnig BA.

J Urol. 2012 Jun;187(6):2026-31. doi: 10.1016/j.juro.2012.01.070. Epub 2012 Apr 11.

PMID:
22498210
[PubMed - indexed for MEDLINE]
19.

Contemporary evaluation of the D'amico risk classification of prostate cancer.

Hernandez DJ, Nielsen ME, Han M, Partin AW.

Urology. 2007 Nov;70(5):931-5.

PMID:
18068450
[PubMed - indexed for MEDLINE]
20.

What percentage of patients with newly diagnosed carcinoma of the prostate are candidates for surveillance? An analysis of the CaPSURE database.

Barocas DA, Cowan JE, Smith JA Jr, Carroll PR; CaPSURE Investigators.

J Urol. 2008 Oct;180(4):1330-4; discussion 1334-5. doi: 10.1016/j.juro.2008.06.019. Epub 2008 Aug 15.

PMID:
18707731
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk